资讯
Snap-8Anti-wrinkle octapeptide modulating SNARE complex activity. Peptide-based alternative for expression line reduction.
TB500Thymosin Beta-4 fragment for tissue remodeling, cell migration and recovery. The natural companion to BPC-157 in dual-recovery stacks.
TesamorelinGHRH analog clinically studied for visceral fat reduction. Selectively targets abdominal adipose while preserving lean tissue.
Tesamorelin10mg+Ipamorelin5mgTesamorelin and Ipamorelin dual-pathway GH stack. GHRH and ghrelin receptor activation from one vial.
Thymalin/ThymulinThymic bioregulator restoring T-lymphocyte function and immune competence. Classic compound in immune-rejuvenation programs.
Thymosin Alpha-1Immune-modulating peptide enhancing T-cell, dendritic cell and NK function. Frontline compound in immune support protocols.
TirzepatideDual GIP/GLP-1 agonist for advanced metabolic and weight-management protocols. One of the most studied incretin peptides in modern metabolic science.
VIPNeuro-immune peptide regulating tolerance, inflammation and circadian rhythm. Versatile support for autoimmune and CNS protocols.
Bacteriostatic WaterSterile bac water with 0.9% benzyl alcohol for safe multi-dose peptide reconstitution. The essential diluent for any peptide protocol.
FDA Approves MIMRYLO (Rusfertide), a Hepcidin-Mimetic Peptide for Polycythemia VeraThe FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
- FDA Grants Fast Track to PVX108 Peanut Peptide Immunotherapy
PVX108 received FDA Fast Track designation in August 2026 as a synthetic T-cell epitope peptide therapy for peanut allergy—one of the first allergen immunotherapy programs built entirely on short peptides rather than whole extracts.
- GLP-1 Bulk-Drug Comment Period Closes; Thousands of Filings on 503B Peptide Access
FDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.
- Lilly Reports Phase 3 TRIUMPH Data for Retatrutide, a GLP-1/GIP/Glucagon Triple Agonist
Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.
- FDA Advisory Panel Backs Six Peptides for 503A Bulks-List Consideration
The FDA Pharmacy Compounding Advisory Committee recommended six peptide bulk substances for 503A list consideration after two days of safety, sourcing, and dosing testimony in July 2026.
- Ketone Esters Plus Semaglutide: Preclinical Data on Muscle Preservation Draws Attention
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.
- ENDO 2026: GLP-1 and Multi-Agonist Peptides Dominate Chicago Readouts
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.
- Solvent Recovery and Waste-Intensity Metrics Enter Peptide Supplier Scorecards
Peptide suppliers face new scorecard metrics on solvent recovery and waste intensity in 2026.
- Focusing on green production, peptide factories help promote sustainable development in the skincare
Focusing on green production: peptide factories and sustainable skincare development.
- Empowering small and medium-sized beauty enterprises, peptide factories become industry development
Empowering small and medium-sized beauty enterprises: how peptide factories support industry development.
- Technology empowers quality upgrade, peptide factory opens up a new track for industry development
Technology empowers quality upgrade in peptide factories.